Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$86.46 USD
+1.76 (2.08%)
Updated May 14, 2024 04:00 PM ET
After-Market: $86.44 -0.02 (-0.02%) 4:44 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EW 86.46 +1.76(2.08%)
Will EW be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EW
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
Top Analyst Reports for Salesforce, BP & Southern Co.
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALC vs. EW: Which Stock Is the Better Value Option?
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
Other News for EW
Roblox downgraded, Western Digital initiated: Wall Street's top analyst calls
Edwards Lifesciences: A Buy Rating with Strong Growth Prospects and Positive Market Dynamics
Edwards Lifesciences just upgraded at Deutsche Bank, here's why
Indian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust Complaint
India's Meril files EU antitrust complaint against Edwards: report